Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
UNIVERSITA AUTÒNOMA DE BARCELONA is engaged in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. This level of activity shows an ongoing approach to securing intellectual property within the biotechnology field. The presence of 2 pending office actions indicates that the university is managing multiple active applications simultaneously.
The prosecution is distributed across 2 distinct art units and involves 2 distinct examiners. This distribution suggests that the university's 2 pending office actions cover a variety of sub-specialties within the Biotechnology & Pharmaceuticals area. Having 2 distinct examiners provides more variety in feedback than a portfolio with only 1 distinct examiner.
ALLEN, SARAH ELIZABETH is the busiest examiner for the portfolio, with a busiest examiner pending count of 1. This examiner is responsible for 1 of the 2 pending office actions. The fact that ALLEN, SARAH ELIZABETH is the busiest examiner with a count of 1 highlights the even distribution of the workload across the 2 distinct examiners currently assigned to the university's matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, SARAH ELIZABETH | 1 | 57.1% | +50.0% |
| MOORE, JOHN DAVID | 1 | 64.2% | +24.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18003980 | MODIFIED INSULIN AND GLUCOKINASE NUCLEIC ACIDS FOR TREATING DIABETES | ALLEN, SARAH ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17384533 | VIRAL VECTORS FOR THE TREATMENT OF DIABETES | MOORE, JOHN DAVID | 44d overdue |
| 18003980 | MODIFIED INSULIN AND GLUCOKINASE NUCLEIC ACIDS FOR TREATING DIABETES | ALLEN, SARAH ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18003980 | MODIFIED INSULIN AND GLUCOKINASE NUCLEIC ACIDS FOR TREATING DIABETES | ALLEN, SARAH ELIZABETH | 1637 | §102§103§112Other | Non-Final OA | — | Pending | Dec 30, 2022 |
| 17384533 | VIRAL VECTORS FOR THE TREATMENT OF DIABETES | MOORE, JOHN DAVID | 1638 | §103 | Non-Final OA | 44d overdue | Pending | Jul 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial